Alimentary pharmacology & therapeutics · 2025
Prevalence of Opioid Use and Associated Healthcare Outcomes in Rome IV Irritable Bowel Syndrome in the United Kingdom.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Butt Mohsin F, Goodoory Vivek C, Ng Cho Ee, Black Christopher J, Ford Alexander C, Corsetti Maura, Paine Peter
Аннотация
BACKGROUND: The United Kingdom (UK) has one of the highest worldwide opioid prescription rates per capita. International guidelines caution against the use of opioids for chronic non-malignant pain, including irritable bowel syndrome (IBS).
AIMS: To study the prevalence and impact of regular opioid use among people with Rome IV IBS in community settings in the UK.
METHODS: We collected demographic, quality of life (QoL), psychological symptoms, and healthcare utilisation data from 752 people with Rome IV IBS. Participants were recruited via electronic mailshot in July 2021 through ContactME-IBS, a UK registry of persons diagnosed with IBS primarily by a general practitioner or gastroenterologist.
RESULTS: Among participants, 148 (19.7%) reported taking an opioid regularly. The prevalence of opioid use did not vary across IBS subtypes (p = 0.10). Disease-specific and generic QoL were lower among opioid users than non-users (p < 0.001, both analyses). Compared with non-users, a greater proportion of opioid users had anxiety or depression (p < 0.001, both analyses) and greater overall activity impairment (p < 0.001). The direct healthcare costs related to investigations (p = 0.003), IBS-related medications (p < 0.001), and unplanned hospital attendances (p < 0.001) were greater among participants who used opioids. Opioid users also expressed a greater willingness to accept the risk of death in return for a cure of IBS symptoms from a hypothetical medication (p = 0.002).
CONCLUSION: Approximately one in five people with Rome IV IBS used opioids on a regular basis. Compared with non-users, opioid users had worse QoL, greater psychological impairment, and higher direct healthcare costs.
AIMS: To study the prevalence and impact of regular opioid use among people with Rome IV IBS in community settings in the UK.
METHODS: We collected demographic, quality of life (QoL), psychological symptoms, and healthcare utilisation data from 752 people with Rome IV IBS. Participants were recruited via electronic mailshot in July 2021 through ContactME-IBS, a UK registry of persons diagnosed with IBS primarily by a general practitioner or gastroenterologist.
RESULTS: Among participants, 148 (19.7%) reported taking an opioid regularly. The prevalence of opioid use did not vary across IBS subtypes (p = 0.10). Disease-specific and generic QoL were lower among opioid users than non-users (p < 0.001, both analyses). Compared with non-users, a greater proportion of opioid users had anxiety or depression (p < 0.001, both analyses) and greater overall activity impairment (p < 0.001). The direct healthcare costs related to investigations (p = 0.003), IBS-related medications (p < 0.001), and unplanned hospital attendances (p < 0.001) were greater among participants who used opioids. Opioid users also expressed a greater willingness to accept the risk of death in return for a cure of IBS symptoms from a hypothetical medication (p = 0.002).
CONCLUSION: Approximately one in five people with Rome IV IBS used opioids on a regular basis. Compared with non-users, opioid users had worse QoL, greater psychological impairment, and higher direct healthcare costs.